Sign inStart free

10-Q quarterly report · filed Aug 5, 2026

Vir Biotechnology, Inc. (VIR) Q2 2026 10-Q Quarterly Report

VIR overviewOriginal on SEC EDGAR
Follow VIR for alertsAsk AI about VIR

Short answer

Vir Biotechnology, Inc. (VIR) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $239M (up 19582.5% year over year) with net income of $80M.

Q2 2026 key financials · XBRL

Revenue
$239M
+19582.5% YoY
Net income
$80M
+172.2% YoY · +163.7% QoQ
Operating margin
30.7%
EPS (diluted)
$0.56
+170.0% YoY · +165.9% QoQ

Source: XBRL data from the Vir Biotechnology, Inc. (VIR) Q2 2026 10-Q on SEC EDGAR. USD.

Vir Biotechnology, Inc. Q2 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $238.9M, up $237.7M YoY from $1.2M, driven by $239.3M Astellas collaboration revenue
  • Net income $80.1M vs $111.0M loss YoY; operating income $73.5M vs $118.4M loss
  • R&D expenses $135.3M, up $37.8M YoY; $48.0M Sanofi payment and higher manufacturing costs
  • Cash, cash equivalents and investments $1.01B at June 30; Astellas provided $315.0M during Q2
  • ECLIPSE 1 topline data expected Q4 2026; ECLIPSE 2 and 3 data expected Q1 2027
  • Existing liquidity expected to fund operations at least 12 months; additional capital may be required

Risk Factors

  • New AI deployment risk added for antibody discovery, with competitors potentially using AI more effectively
  • Materially updated financial risk: $1.01 billion cash, cash equivalents and investments expected to fund operations at least 12 months
  • Regulatory risk: FDA may require additional studies or alter development requirements, delaying approvals and increasing compliance costs
  • Clinical risk: oncology trials in critically ill patients may involve serious adverse events, including death
  • Financial-market risk: capital-market volatility, interest-rate and currency fluctuations may restrict financing access or increase financing costs

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Vir Biotechnology, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.

Start free